Current Gastroenterology Reports

, Volume 10, Issue 1, pp 15–21 | Cite as

Pregnancy and liver disease



Although liver disease does not occur frequently during pregnancy, when it does, it can cause significant morbidity and mortality for both fetus and mother. Recent advances in molecular genetics have provided some insight into the pathogenesis of diseases such as intrahepatic cholestasis of pregnancy (IHCP) and acute fatty liver of pregnancy. Newer studies linking serum bile acid levels with fetal outcome support the importance of this marker in IHCP. Randomized trials with ursodeoxycholic acid have shown promising results in reducing maternal symptoms and serum bile acid levels in IHCP. Although further studies must be performed, early strategies aimed at reducing viral loads in mothers may reduce perinatal transmission of hepatitis B.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dodds L, Fell DB, Joseph KS, et al.: Outcomes of pregnancies complicated by hyperemesis gravidarum. Obstet Gynecol 2006, 107:285–292.PubMedGoogle Scholar
  2. 2.
    Lee RH, Goodwin TM, Greenspoon J, et al.: The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol 2006, 26:527–532.PubMedCrossRefGoogle Scholar
  3. 3.
    Schneider G, Paus TC, Kullak-Ublick GA, et al.: Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology 2007, 45:150–158.PubMedCrossRefGoogle Scholar
  4. 4.
    Floreani A, Carderi I, Paternoster D, et al.: Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther 2006, 23:1649–1653.PubMedCrossRefGoogle Scholar
  5. 5.
    Poupon R: Intrahepatic cholestasis of pregnancy: from bedside to bench to bedside. Liver Int 2005, 25:467–468.PubMedCrossRefGoogle Scholar
  6. 6.
    Beuers U, Pusl T: Intrahepatic cholestasis of pregnancy-a heterogeneous group of pregnancy-related disorders? Hepatology 2006, 43:647–649.PubMedCrossRefGoogle Scholar
  7. 7.
    Reyes H, Zapata R, Hernandez I, et al.: Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? Hepatology 2006, 43:715–722.PubMedCrossRefGoogle Scholar
  8. 8.
    Glantz A, Marschall HU, Mattsson LA: Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 2004, 40:467–474.PubMedCrossRefGoogle Scholar
  9. 9.
    Binder T, Salaj P, Zima T, et al.: Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006, 34:383–391.PubMedCrossRefGoogle Scholar
  10. 10.
    Glantz A, Marschall HU, Lammert F, et al.: Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005, 42:1399–1405.PubMedCrossRefGoogle Scholar
  11. 11.
    Sentilhes L, Verspyck E, Roman H, et al.: Intrahepatic cholestasis of pregnancy and bile acid levels. Hepatology 2005, 42:737–738; author reply 738.PubMedCrossRefGoogle Scholar
  12. 12.
    Sentilhes L, Verspyck E, Pia P, et al.: Fetal death in a patient with intrahepatic cholestasis of pregnancy. Obstet Gynecol 2006, 107:458–460.PubMedGoogle Scholar
  13. 13.
    Alsulyman OM, Ouzounian JG, Ames-Castro M, et al.: Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. Am J Obstet Gynecol 1996, 175:957–960.PubMedCrossRefGoogle Scholar
  14. 14.
    Kondrackiene J, Beuers U, Kupcinskas L: Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005, 129:894–901.PubMedCrossRefGoogle Scholar
  15. 15.
    Weinstein L: Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982, 142:159–167.PubMedGoogle Scholar
  16. 16.
    Sibai BM, Ramadan MK, Usta I, et al.: Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993, 169:1000–1006.PubMedGoogle Scholar
  17. 17.
    Guntupalli SR, Steingrub J: Hepatic disease and pregnancy: an overview of diagnosis and management. Crit Care Med 2005, 33:S332–S339.PubMedCrossRefGoogle Scholar
  18. 18.
    Martin JN, Jr, Rose CH, Briery CM: Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006, 195:914–934.PubMedCrossRefGoogle Scholar
  19. 19.
    Sibai BM, Taslimi MM, el-Nazer A, et al.: Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986, 155:501–509.PubMedGoogle Scholar
  20. 20.
    O’Brien JM, Barton JR: Controversies with the diagnosis and management of HELLP syndrome. Clin Obstet Gynecol 2005, 48:460–477.PubMedCrossRefGoogle Scholar
  21. 21.
    Martin JN, Jr, Rinehart BK, May WL, et al.: The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999, 180:1373–1384.PubMedCrossRefGoogle Scholar
  22. 22.
    Magann EF, Bass D, Chauhan SP, et al.: Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994, 171:1148–1153.PubMedGoogle Scholar
  23. 23.
    Magann EF, Perry KG, Jr, Meydrech EF, et al.: Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994, 171:1154–1158.PubMedGoogle Scholar
  24. 24.
    Isler CM, Barrilleaux PS, Magann EF, et al.: A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2001, 184:1332–1337, discussion 1337–1339.PubMedCrossRefGoogle Scholar
  25. 25.
    Tompkins MJ, Thiagarajah S: HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids. Am J Obstet Gynecol 1999, 181:304–309.PubMedCrossRefGoogle Scholar
  26. 26.
    Martin JN, Jr, Files JC, Blake PG, et al.: Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1995, 172:1107–1125, discussion 1125–1127.PubMedCrossRefGoogle Scholar
  27. 27.
    Martin JN, Jr, Perry KG, Jr, Roberts WE, et al.: Plasma exchange for preeclampsia: III. Immediate peripartal utilization for selected patients with HELLP syndrome. J Clin Apher 1994, 9:162–165.PubMedCrossRefGoogle Scholar
  28. 28.
    Smith LG, Jr, Moise KJ, Jr, Dildy GA III, et al.: Spontaneous rupture of liver during pregnancy: current therapy. Obstet Gynecol 1991, 77:171–175.PubMedCrossRefGoogle Scholar
  29. 29.
    Ibdah JA, Bennett MJ, Rinaldo P, et al.: A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999, 340:1723–1731.PubMedCrossRefGoogle Scholar
  30. 30.
    Ibdah JA: Acute fatty liver of pregnancy: an update on pathogenesis and clinical implications. World J Gastroenterol 2006, 12:7397–7404.PubMedGoogle Scholar
  31. 31.
    Browning MF, Levy HL, Wilkins-Haug LE, et al.: Fetal fatty acid oxidation defects and maternal liver disease in pregnancy. Obstet Gynecol 2006, 107:115–120.PubMedGoogle Scholar
  32. 32.
    Chang MH: Hepatitis B virus infection. Semin Fetal Neonatal Med 2007, 12:160–167.PubMedCrossRefGoogle Scholar
  33. 33.
    Ngui SL, Andrews NJ, Underhill GS, et al.: Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998, 27:100–106.PubMedCrossRefGoogle Scholar
  34. 34.
    del Canho R, Grosheide PM, Mazel JA, et al.: Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982–1992: protective efficacy and long-term immunogenicity. Vaccine 1997, 15:1624–1630.PubMedCrossRefGoogle Scholar
  35. 35.
    van Zonneveld M, van Nunen AB, Niesters HG, et al.: Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003, 10:294–297.PubMedCrossRefGoogle Scholar
  36. 36.
    Su GG, Pan KH, Zhao NF, et al.: Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004, 10:910–912.PubMedGoogle Scholar
  37. 37.
    Xu WM, Cui YT, Wang L, et al.: Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicentre, randomised, double blind, placebo-controlled study [abstract 246]. Hepatology 2004, 40:272A.Google Scholar
  38. 38.
    Xiao XM, Li AZ, Chen X, et al.: Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 2007, 96:167–170.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Ann Arbor Veterans Administration Health CenterUniversity of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations